Antiplatelet drug 'resistance'. Part 1: mechanisms and clinical measurements (Q37437158)

20 August 2017

1 reference

title

Antiplatelet drug 'resistance'. Part 1: mechanisms and clinical measurements (English)

1 reference

20 August 2017

author

Valentín Fuster Carulla

series ordinal

3

1 reference

20 August 2017

Joseph M Sweeny

1

1 reference

20 August 2017

Diana A Gorog

series ordinal

2

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 April 2009

1 reference

Nature Reviews Cardiology

20 August 2017

published in

1 reference

20 August 2017

volume

6

1 reference

20 August 2017

issue

4

1 reference

20 August 2017

page(s)

273-282

1 reference

Toward a new frontier in myocardial reperfusion therapy: emerging platelet preeminence

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Platelet turnover in advanced diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Ibuprofen protects platelet cyclooxygenase from irreversible inhibition by aspirin

21 January 2018

2 references

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

21 January 2018

12 December 2020

Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Are we mortgaging the medical profession?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

The role of platelet receptors and adhesion molecules in coronary artery disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Geographical differences in the rates of angiographic restenosis and ischemia-driven target vessel revascularization after percutaneous coronary interventions: results from the Prevention of Restenosis With Tranilast and its Outcomes (PRESTO) Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Variable platelet response to aspirin and clopidogrel in atherothrombotic disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Salicylates and bleeding: the aspirin tolerance test

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Prasugrel versus clopidogrel in patients with acute coronary syndromes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

One hundred years of aspirin.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

31 March 2020

COX-3: fact or fancy?

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Aspirin and clopidogrel resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Aspirin and coronary artery disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Laboratory detection of 'aspirin resistance': what test should we use (if any)?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Platelet function monitoring in patients with coronary artery disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Growth arrest specific gene (GAS) 6 modulates platelet thrombus formation and vascular wall homeostasis and represents an attractive drug target

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Towards a definition of aspirin resistance: a typological approach

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

The genetics of antiplatelet drug resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Cyclooxygenase-1 haplotype modulates platelet response to aspirin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Resistance in vitro to low-dose aspirin is associated with platelet PlA1 (GP IIIa) polymorphism but not with C807T(GP Ia/IIa) and C-5T Kozak (GP Ibalpha) polymorphisms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Cyclooxygenase inhibitors and the antiplatelet effects of aspirin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Long-term adherence with cardiovascular drug regimens

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Antiplatelet effect of aspirin in patients with cerebrovascular disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Clinical implications of clopidogrel resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Individual variations of platelet inhibition after loading doses of clopidogrel

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Variability in platelet responsiveness to clopidogrel among 544 individuals.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Platelet function testing in cardiovascular diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Cytochrome p-450 polymorphisms and response to clopidogrel

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Adherence to secondary stroke prevention strategies--results from the German Stroke Data Bank

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

The "clopidogrel resistance" trap

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Determination of clopidogrel main metabolite in plasma: a useful tool for monitoring therapy?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Ef

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Phosphorylation of focal adhesion vasodilator-stimulated phosphoprotein at Ser157 in intact human platelets correlates with fibrinogen receptor inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

31 March 2020

Clopidogrel resistance?

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Resistance to clopidogrel: a review of the evidence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

The role of aspirin resistance on outcome in patients with acute coronary syndrome and the effect of clopidogrel therapy in the prevention of major cardiovascular events

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Aspirin resistance measured by cationic propyl gallate platelet aggregometry and recurrent cardiovascular events during 4 years of follow-up

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Enhanced shear-induced platelet aggregation in patients who experience subacute stent thrombosis: a case-control study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platele

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.10

Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement

31 March 2020

1 reference

12 December 2020

Dissociation of platelet activation and spontaneous myocardial ischemia in unstable angina

1 reference

12 December 2020

ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention—Summary Article

1 reference

12 December 2020

The pathogenesis of coronary artery disease and the acute coronary syndromes (1).

1 reference

12 December 2020

Atherosclerotic plaque rupture and thrombosis. Evolving concepts

1 reference

12 December 2020

Clopidogrel response variability and future therapies: clopidogrel: does one size fit all?

1 reference

12 December 2020

Lack of aspirin effect: aspirin resistance or resistance to taking aspirin?

1 reference

12 December 2020

The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A

1 reference

12 December 2020

Genetics of platelet receptor single-nucleotide polymorphisms: clinical implications in thrombosis.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRCARDIO.2009.10

1 reference

20 August 2017

1 reference